| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
S55746 (formerly known as S-055746 and BCL201) is a novel, potent, selective and orally bioactive BCL-2 inhibitor with Ki of 1.3 nM. The hydrophobic groove of BCL-2 is occupied by S55746. Its selectivity profile shows that it has a weak affinity for BCL-XL and no significant binding to MCL-1 or BFL-1 (BCL2A1/A1). As a result, BCL-XL-dependent cells like platelets are not cytotoxically affected by S55746. S55746 causes a panel of hematological cell lines to externalize phosphatidylserine, activate caspase-3, and cleave PARP, which are all signs of apoptosis. In primary patient samples of chronic lymphocytic leukemia and mantle cell lymphoma, S55746 induces apoptosis in the low nanomolar range. Finally, S55746 demonstrated strong anti-tumor efficacy in two hematological xenograft models when it was given orally to mice daily, with no weight loss and no behavioral changes. These findings show that S55746 is a potent, novel, and well-tolerated BH3-mimetic that targets the BCL-2 protein.
| Targets |
Bcl-2 (Ki = 1.3 nM); Bcl-xL (Ki = 520 nM); Bcl-2 (Ki = 3.9 nM); Bcl-xL (Ki = 186 nM)
|
|---|---|
| ln Vitro |
S55746 is located in BCL-2's hydrophobic groove. S55746 causes the externalization of phosphatidylserine, caspase-3 activation, and PARP cleavage in a panel of hematological cell lines, which are signs of apoptosis. S55746 exhibits much weaker activity in H146 (IC50 = 1.7 μM), a BCL-XL-dependent cell line, which expresses high levels of BCL-XL and low levels of BCL-2. S55746 potently induces RS4;11 cell killing after 72 hours of treatment with an IC50 of 71.6 nM. On BCL-XL-dependent cells, like platelets, it has no cytotoxic activity[1].
|
| ln Vivo |
S55746 exhibits strong anti-tumor efficacy in two hematological xenograft models (RS4;11 and Toledo models) when given orally daily to mice, with no weight loss and no behavioral changes[1].
|
| Cell Assay |
Apoptosis induction in RS4;11 cells subjected to a 2-hour treatment with S55746 at various concentrations. PI and annexin V-FITC labeled cells were examined using flow cytometry.
|
| References |
| Molecular Formula |
C43H42N4O6
|
|
|---|---|---|
| Molecular Weight |
710.83
|
|
| Exact Mass |
710.31
|
|
| Elemental Analysis |
C, 72.66; H, 5.96; N, 7.88; O, 13.50
|
|
| CAS # |
1448584-12-0
|
|
| Related CAS # |
S55746 hydrochloride;1448525-91-4
|
|
| Appearance |
Solid powder
|
|
| SMILES |
C1CCN2C(=C(C=C2C3=CC4=C(C=C3C(=O)N5CC6=CC=CC=C6C[C@H]5CN7CCOCC7)OCO4)C(=O)N(C8=CC=CC=C8)C9=CC=C(C=C9)O)C1
|
|
| InChi Key |
VYXJULKGMXJVGI-XIFFEERXSA-N
|
|
| InChi Code |
InChI=1S/C43H42N4O6/c48-34-15-13-32(14-16-34)47(31-10-2-1-3-11-31)43(50)37-23-39(45-17-7-6-12-38(37)45)35-24-40-41(53-28-52-40)25-36(35)42(49)46-26-30-9-5-4-8-29(30)22-33(46)27-44-18-20-51-21-19-44/h1-5,8-11,13-16,23-25,33,48H,6-7,12,17-22,26-28H2/t33-/m0/s1
|
|
| Chemical Name |
N-(4-hydroxyphenyl)-3-[6-[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydro-1H-isoquinoline-2-carbonyl]-1,3-benzodioxol-5-yl]-N-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 5.75 mg/mL (8.09 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 57.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.52 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.52 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4068 mL | 7.0340 mL | 14.0681 mL | |
| 5 mM | 0.2814 mL | 1.4068 mL | 2.8136 mL | |
| 10 mM | 0.1407 mL | 0.7034 mL | 1.4068 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02920697 | Completed | Drug: S 55746 | Multiple Myeloma (MM) Chronic Lymphocytic Leukaemia (CLL) |
Institut de Recherches Internationales Servier |
March 2014 | Phase 1 |
| NCT02603445 | Completed | Drug: BCL201 Drug: Idelalisib |
Follicular Lymphoma, Mantle Cell Lymphoma |
Novartis Pharmaceuticals | November 16, 2015 | Phase 1 |
S55746 is a potent and selective inhibitor of BCL-2. |
S55746 induces cell death in a panel of non-Hodgkin lymphoma cell lines. |
S55746 induces cell death in primary CLL and MCL cells.Oncotarget.2018 Apr 13;9(28):20075-20088 |
S55746 induces apoptosis in a BAX-dependent manner.Oncotarget.2018 Apr 13;9(28):20075-20088. |
S55746 inhibits xenograft growth in RS4;11 and Toledo models.Oncotarget.2018 Apr 13;9(28):20075-20088. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
